Codrin C Constantin Burlacu

Mr. Codrin C Constantin Burlacu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CBCodrin C Constantin Burlacu
Codrin C Constantin Burlacu
MNMaria Neag
Maria Neag
AMAndrei Mitre
Andrei Mitre
ASAlexandru-Constantin Sirbu
Alexandru-Constantin Sirbu
ABAndrei-Vlad Badulescu
Andrei-Vlad Badulescu
ABAnca Dana Buzoianu
Anca Dana Buzoianu
There are limited neuroprotective strategies for various central nervous system conditions in which fast and sustained management is essential. Neuroprotection-based therapeutics have become an intensively researched topic in the neuroscience field, with multiple novel promising agents, from natural products to mesenchymal stem cells, homing peptides, and nanoparticles-mediated agents, all aiming to significantly provide neuroprotection in experimental and clinical studies. Dexmedetomidine (DEX), an α2 agonist commonly used as an anesthetic adjuvant for sedation and as an opioid-sparing medication, stands out in this context due to its well-established neuroprotective effects. Emerging evidence from preclinical and clinical studies suggested that DEX could be used to protect against cerebral ischemia, traumatic brain injury (TBI), spinal cord injury, neurodegenerative diseases, and postoperative cognitive disorders. MicroRNAs (miRNAs) regulate gene expression at a post-transcriptional level, inhibiting the translation of mRNA into functional proteins. In vivo and in vitro studies deciphered brain-related miRNAs and dysregulated miRNA profiles after several brain disorders, including TBI, ischemic stroke, Alzheimer’s disease, and multiple sclerosis, providing emerging new perspectives in neuroprotective therapy by modulating these miRNAs. Experimental studies revealed that some of the neuroprotective effects of DEX are mediated by various miRNAs, counteracting multiple mechanisms in several disease models, such as lipopolysaccharides induced neuroinflammation, β-amyloid induced dysfunction, brain ischemic-reperfusion injury, and anesthesia-induced neurotoxicity models. This review aims to outline the neuroprotective mechanisms of DEX in brain disorders by modulating miRNAs. We address the neuroprotective effects of DEX by targeting miRNAs in modulating ischemic brain injury, ameliorating the neurotoxicity of anesthetics, reducing postoperative cognitive dysfunction, and improving the effects of neurodegenerative diseases.

Verified
Journal Article
Open access
PDF file
CBCodrin C Constantin Burlacu
Codrin C Constantin Burlacu
CDCIOBANU DANIELA
CIOBANU DANIELA
ABAndrei-Vlad Badulescu
Andrei-Vlad Badulescu
VCVlad-Florin Chelaru
Vlad-Florin Chelaru
AMAndrei Mitre
Andrei Mitre
Aurel Popa-WagnerAurel Popa-Wagner
Aurel Popa-Wagner
Stroke accounts for the second leading cause of death and a major cause of disability, with limited therapeutic strategy in both the acute and chronic phases. Blood-based biomarkers are intensively researched and widely recognized as useful tools to predict the prognoses of patients confronted with therapeutically limited diseases. We performed a systematic review of the circulating biomarkers in IS patients with prognostic value, with a focus on microRNAs and exosomes as predictive biomarkers of motor and cognitive recovery. We identified 63 studies, totalizing 72 circulating biomarkers with prognostic value in stroke recovery, as follows: 68 miRNAs and exosomal-miRNAs being identified as predictive for motor recovery after stroke, and seven biomarkers being predictive for cognitive recovery. Twelve meta-analyses were performed using effect sizes (random-effects and fixed-effects model). The most significant correlation findings obtained after pooling were with miR-21, miR-29b, miR-125b-5p, miR-126, and miR-335. We identified several miRNAs that were correlated with clinical outcomes of stroke severity and recovery after ischemic stroke, providing predictive information on motor and cognitive recovery. Based on the current state of research, we identified serum miR-9 and neutrophil miR-29b as the most promising biomarkers for in-depth follow-up studies, followed by serum miR-124 and plasma miR-125b.

18 October 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
GMGheorghe-Eduard Marin
Gheorghe-Eduard Marin
MNMaria Neag
Maria Neag
CBCodrin C Constantin Burlacu
Codrin C Constantin Burlacu
ABAnca Dana Buzoianu
Anca Dana Buzoianu
There are multiple concerns associated with methotrexate (MTX), widely recognized for anti-neoplastic and anti-inflammatory effects in life-threatening disease conditions, i.e., acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, psoriasis, and rheumatoid arthritis, due to long-term side effects and associated toxicity, which limits its valuable potential. MTX acts as an inhibitor of dihydrofolate reductase, leading to suppression of purine and pyrimidine synthesis in high metabolic and turnover cells, targeting cancer and dysregulated immune cells. Due to low discrimination between neoplastic cells and naturally high turnover cells, MTX is prone to inhibiting the division of all fast-dividing cells, causing toxicity in multiple organs. Nutraceutical compounds are plant-based or food-derived compounds, used for their preventive and therapeutic role, ascertained in multiple organ dysfunctions, including cardiovascular disease, ischemic stroke, cancer, and neurodegenerative diseases. Gut microbiota and microbiota-derived metabolites take part in multiple physiological processes, their dysregulation being involved in disease pathogenesis. Modulation of gut microbiota by using nutraceutical compounds represents a promising therapeutic direction to restore intestinal dysfunction associated with MTX treatment. In this review, we address the main organ dysfunctions induced by MTX treatment, and modulations of them by using nutraceutical compounds. Moreover, we revealed the protective mechanisms of nutraceuticals in MTX-induced intestinal dysfunctions by modulation of gut microbiota.

15 February 2023 in Medicine and Pharmacy Reports
Verified
Journal Article
Open access
PDF file
CBCodrin C Constantin Burlacu
Codrin C Constantin Burlacu
VCVlad-Florin Chelaru
Vlad-Florin Chelaru
Tudor DruganTudor Drugan
Tudor Drugan
ABAndrei-Vlad Badulescu
Andrei-Vlad Badulescu
Background and aims. The COVID-19 lockdowns are reported to have negatively influenced the wellbeing and learning efficacy of students. In this context, we analyzed the psychological impact of the COVID-19 quarantine on healthcare students, a subpopulation experiencing high stress levels. Methods. Our survey-based, cross-sectional study assessed wellbeing indicators, lifestyle and learning behaviors before and during the quarantine for 388 Romanian healthcare students. Results. Our findings included the increase in phone and social media use, at the expense of formal and independent study time; deteriorations in mood, self-organization capacity and learning efficacy, and increased procrastination behaviors. Unexpectedly, our study identified an improvement in sleep quality and duration. The increase in social media use was less severe among rural students. We identified correlations between study time, online activities (including social media), wellbeing indicators and procrastination. Conclusion. Our study draws attention to quarantine-induced deteriorations of wellbeing and learning capacity in an important category of students.